Literature DB >> 16216448

Characterization of a complex genomic alteration on chromosome 2p that leads to four alternatively spliced fusion transcripts in the neuroblastoma cell lines IMR-5, IMR-5/75 and IMR-32.

André Oberthuer1, Matthias Skowron, Rüdiger Spitz, Yvonne Kahlert, Frank Westermann, Kathrin Mehler, Frank Berthold, Matthias Fischer.   

Abstract

Genetic aberrations in neuroblastoma (NB) have been extensively characterized over the last years. Alterations of the short arm of chromosome 2 (2p) have been of particular interest, since amplification of the MYCN oncogene on 2p24 is associated with an adverse outcome in NB patients. Here, we report on the characterization of a novel genomic rearrangement involving genetic material from 2p13 and 2p24 in NB cell lines that was discovered based on a serial analysis of gene expression (SAGE) profile of the MYCN-amplified NB cell line IMR-5. By analysis of a highly expressed SAGE tag not matching a Unigene cluster we identified four alternatively spliced corresponding transcripts, each of which consisted of the first 14 exons of the anthrax toxin receptor 1 gene (2p13.1) and varying combinations of exons of an unidentified gene located 1.3 Mb telomeric of MYCN (2p24.3) that was termed novel neuroblastoma gene 1. By Southern Blotting, Fluorescent In Situ Hybridization and Long Distance Inverse-PCR we disclosed that these transcripts result from a genomic alteration including material from distinct regions of chromosome 2p and four genomic breakpoints that are joined by short sequences of unknown origin. Furthermore, we show that this rearrangement lies within the homogeneous staining regions (HSR) in IMR-32 cells and is prevalent in both IMR-32 cells and their sub-clones IMR-5 and IMR-5/75, but not in a panel of 70 primary NB tumors. Our work is the first study discovering a fusion transcript based on a SAGE profile and for the first time precisely describes the DNA sequence of amplified breakpoint regions in NB.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16216448     DOI: 10.1016/j.gene.2005.07.038

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  5 in total

1.  Detection of human tumor cells by amplicon fusion site polymerase chain reaction (AFS-PCR).

Authors:  Axel Weber; Sylvia Taube; Sven Starke; Eckhard Bergmann; Nina Merete Christiansen; Holger Christiansen
Journal:  J Clin Invest       Date:  2011-02       Impact factor: 14.808

2.  A unique cytogenetic abnormality, t(2;7)(p13.1;p21.3), in a Philadelphia-positive chronic myeloid leukemia.

Authors:  Walid Al-Achkar; Abdulsamad Wafa; Faten Moassass; Thomas Liehr
Journal:  Oncol Lett       Date:  2012-05-17       Impact factor: 2.967

3.  Association of a germ-line copy number variation at 2p24.3 and risk for aggressive prostate cancer.

Authors:  Wennuan Liu; Jishan Sun; Ge Li; Yi Zhu; Scott Zhang; Seong-Tae Kim; Jielin Sun; Fredrik Wiklund; Kathleen Wiley; Sarah D Isaacs; Pär Stattin; Jianfeng Xu; David Duggan; John D Carpten; William B Isaacs; Henrik Grönberg; S Lilly Zheng; Bao-Li Chang
Journal:  Cancer Res       Date:  2009-03-03       Impact factor: 12.701

4.  Broad expression analysis of human ANTXR1/TEM8 transcripts reveals differential expression and novel splizce variants.

Authors:  Micaela Vargas; Raghavendra Karamsetty; Stephen H Leppla; G Jilani Chaudry
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

5.  Intact-Cell MALDI-ToF Mass Spectrometry for the Authentication of Drug-Adapted Cancer Cell Lines.

Authors:  Jane F Povey; Emily Saintas; Adewale V Aderemi; Florian Rothweiler; Richard Zehner; Wilhelm G Dirks; Jindrich Cinatl; Andrew J Racher; Mark N Wass; C Mark Smales; Martin Michaelis
Journal:  Cells       Date:  2019-10-02       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.